• FDA approves Retevmo for lung cancer subset

    2 days ago - By Healio

    The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.
    The indication applies to use of selpercatinib by adults with locally advanced or metastatic RET fusion-positive NSCLC as detected by an FDA-approved test.
    The multicenter, open-label LIBRETTO-001 trial evaluated selpercatinib - a kinase inhibitor - for 316 patients (median age, 61 years; range, 23-92; 58% female; 49% white, 41% Asian, 5% Black ) with locally advanced or metastatic RET fusion-positive NSCLC. Most patients had ECOG
    Read more ...

     

  • FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers

    FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers

    2 days ago - By MedPageToday

    The FDA granted accelerated approval to selpercatinib for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the agency announced on Wednesday.
    Selpercatinib's tumor-agnostic...
    Read more ...

     

  • FDA OKs Selpercatinib for Adults With RET Fusion+ Solid Tumors

    FDA OKs Selpercatinib for Adults With RET Fusion+ Solid Tumors

    2 days ago - By Medscape

    The approval expands the drug label to include a variety of RET-positive tumor types, including pancreatic and colorectal cancers.
    FDA Approvals
    Read more ...